The Union Ministry of Health and Family Welfare on Saturday announced restrictions on the use of certain Fixed Dose Combinations (FDCs) containing chlorpheniramine maleate and phenylephrine hydrochloride in children below four years of age. The move has been taken citing safety concerns associated with the use of the combination in young children. The restriction applies to FDC medicines containing chlorpheniramine maleate and phenylephrine hydrochloride when intended for children under four. These medicines combine two active pharmaceutical ingredients in a single formulation.

Chlorpheniramine is an antihistamine commonly used to relieve allergy-related symptoms, while phenylephrine is a decongestant used to reduce nasal congestion. The government's decision reflects concerns over the safety of administering such combination medicines to very young children. Children below four years can respond differently to medicines compared with older children and adults, making appropriate dosing and medical supervision particularly important. The restriction is intended to prevent potentially inappropriate use of these FDCs in this age group.

Fixed Dose Combinations are medicines that contain two or more active ingredients in predetermined quantities within a single dosage form. Such combinations can be useful when their ingredients have complementary therapeutic effects, but regulators can restrict particular combinations or age groups when safety concerns arise. The latest government action specifically concerns FDCs containing the two named ingredients and their use in children younger than four. The restriction also serves as a reminder that medicines commonly used for cold, cough, allergy or congestion symptoms should not automatically be considered suitable for young children.

Also Read: Pakistan Minister Warns India Could Weaponise Water Amid Escalating Indus Treaty Dispute

Parents and caregivers may sometimes use over-the-counter preparations based on symptoms alone, but medicines containing multiple active ingredients can carry different risks depending on a child's age and medical circumstances. Healthcare professionals generally consider factors such as a child's age, weight, symptoms and medical history before recommending medication. Parents should therefore check the ingredients and age-related instructions on medicines and consult a qualified doctor or pharmacist when uncertain about whether a particular product is appropriate for a child.

The health ministry's announcement places particular emphasis on the under-four age group, meaning the restriction is specifically directed at children below that age threshold. It does not mean that every medicine containing either chlorpheniramine maleate or phenylephrine hydrochloride is covered by the same restriction in every circumstance; the government's action concerns the specified Fixed Dose Combinations. The move comes as health regulators continue to scrutinise medicines based on their safety, effectiveness and suitability for different patient groups.

FDCs can simplify treatment by combining ingredients, but their use in children requires particular attention because inappropriate combinations or dosages can potentially cause harm. Parents and caregivers of children under four should avoid giving medicines containing the restricted combination unless specifically advised by a healthcare professional in accordance with current regulatory guidance. The government's action is aimed at reducing avoidable risks associated with the use of these FDC medicines among very young children and reinforcing the importance of age-appropriate medication use.

Also Read: CM Satheesan Seeks Rollback Of Mangaluru Railway Jurisdiction Change